Clinical Trial

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-17; most recent amendment 2026-05-20.
Status change: Not Yet Recruiting → Recruiting 2026-02-25
Trial Details
NCT Number NCT07138209
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 228 participants
Start Date 2025-11-07
Primary Completion 2027-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-22